• Management Team

    Day-to-Day Leadership of Gregor

    Steve Weinstein

    Chief Executive Officer

    Mr. Weinstein brings over 20 years of experience as a CEO, entrepreneur, and venture investor across biotech, medical devices, and digital health innovation. As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio, managed the medical device practice, and invested in biotech. Prior to Novartis, he was with Prism Venture Partners, and was a Kauffman Fellow with Mid-Atlantic Venture Funds. Mr. Weinstein holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University.

    Tobias Zutz

    Chief Technology Officer / Founder

    Mr. Zutz founded Gregor Diagnostics in 2016 and served for 5 years as its founding CEO. In 2021 he transitioned to Chief Technology Officer to focus more directly on the technology for Gregor's testing. Prior to founding Gregor he had a decade of R&D experience in assay development and molecular diagnostics. Most recently he was a member of the R&D team at Exact Sciences that developed Cologuard, a non-invasive screening test for colorectal cancer. Prior to Exact, Mr. Zutz was with two small Madison-area biotech companies. He completed a BS in Biochemistry and Genetics and an MS in Biotechnology both from the University of Wisconsin.

    Duncan Whitney

    Chief Scientific Officer

    Mr. Whitney joined Gregor as the Chief Scientific Officer in 2022. He has over 25 years experience developing clinical diagnostics and biotechnology products. Prior to joining Gregor he was one of the founding members of the Lung Cancer Initiative at Johnson & Johnson as the Head of Early Detection, leading global efforts aimed at diagnosing lung cancer at early stages in order to more effectively intercept and treat patients. He previously spent several years leading lung cancer studies at Allegro Diagnostics, and Veracyte (which acquired Allegro in 2014). Mr. Whitney held scientific leadership roles in a number of other emerging diagnostics, pharmaceutical, and biotechnology companies, including Curis (VP Diagnostics), U.S. Genomics (VP R&D), Exact Sciences (VP Technology Development), and Perseptive Biosystems (now part of Thermo Fisher Scientific). He received his PhD at the Massachusetts Institute of Technology, and his B.A from Colby College.

    Emily Breunig

    Director of Clinical and Regulatory

    Ms. Breunig has more than a decade of experience in clinical research in both academic and industry settings. She has worked the last 8 years in biotech start-up companies. She has vast experience in research, clinical trials, regulatory compliance and data analysis. Ms. Breunig completed her BS in Biology from the University of Wisconsin- Madison.

  • Board of Directors

    Experienced Leaders to help shape the future of Gregor

    Lauren Tyra, PhD

    Chief Scientific Officer, Green Park & Golf Ventures

    Michael Partsch

    Chief Venture Officer, WARF

    Mike Partsch is a seasoned medical device venture capitalist and startup CEO bringing extensive operational experience in early-stage university spinouts. His career has included stops at Versant Ventures – a top health care venture fund – and Acuitive Medical Ventures (AMV), which he started. Partsch currently manages the multimillion-dollar WARF Ventures fund, which invests in companies founded to commercialize UW-Madison or Morgridge Institute for Research technologies. Partsch holds an MBA from Carnegie Mellon University, and completed a Kauffman Fellowship.

    Sundu Brahmasandra, PhD

    Independent Director

    Sundu Brahmasandra is an accomplished serial entrepreneur and brings more than 20 years of impressive leadership in all aspects of novel IVD product development, strategic planning, and operational management. Most recently Sundu was the President & COO of NeuMoDx Molecular where he led the development of a multitude of molecular diagnostics assays on the revolutionary NeuMoDx 288 and NeuMoDx 96 Molecular Systems. Prior to NeuMoDx Sundu co-founded HandyLab, Inc and led the development of the HandyLab Jaguar System. Sundu holds a B.Tech in Chemical Engineering from IIT-Madras and a PhD in Chemical Engineering from the University of Michigan, Ann Arbor.

    Steve Weinstein

    Gregor Diagnostics CEO

    Tobias Zutz

    Gregor Diagnostics CTO and Founder

  • Scientific Advisory Board

    These experienced scientists are helping direct our development

    Dr. David Jarrard

    Uro Oncologist- University of Wisconsin

    Dr. Jarrard is the Associate Director of Translational Research at the UW Carbone Cancer Center where he runs a lab focused on prostate cancer diagnosis and treatment and a research interest in biomarkers. In addition to his research, Dr. Jarrard is a board certified Urologic Oncologist at the University of Wisconsin Hospital specializing in urological oncology and prostate surgery. Dr. Jarrard completed medical school at the University of Virginia School of Medicine, residency at the University of Chicago, and a urologic oncology fellowship at Johns Hopkins University.

    Dr. Jason Christiansen

    Industry Executive

    Dr. Christiansen is an experienced research and development leader with expertise in diagnostic assay development, IVD regulatory processes and practices, and clinical laboratory setup and operation. He is currently the Head of Assay Development at Roche Sequencing Solutions. Previously, Dr. Christiansen held the role of VP of Diagnostics at Ignyta (Nasdaq: RXDX) and led the development and implementation of companion diagnostics for their therapeutic pipeline. His responsibilities included the biomarker and regulatory strategy that drove the establishment of a CLIA and IVD development laboratory. Prior to Ignyta, Dr. Christiansen held Sr. Director roles at Genoptix Medical Laboratories and HistoRx and roles of increasing responsibilities at Protedyne Corporation and Molecular Staging Inc. He completed a BS in Physics and a PhD in Biophysics both from the University of California – Davis.

    Dr. Hon Leong

    Researcher- University of Toronto / Sunnybrook Research Institute

    Dr. Leong joined the Sunnybrook Research Institute in 2019 as a Scientist in the Odette Cancer Research Program. His mandate is to bring lab-grown ideas to the clinic, with a particular focus on the genitourinary system (kidney, bladder, prostate, testes, urethra, penis). The constant goal is to take concepts developed in the lab and translate them into clinical practice. The group emphasizes multidisciplinary training and collaboration to help trainees become confident and highly skilled scientists. Dr. Leong comes to Sunnybrook from the Mayo Clinic in Rochester, MN and Western University in London, ON. He completed his BSc at the University of Alberta, his MSc and PhD at the University of British Columbia, and a Postdoctorate Fellowship at the London Health Sciences Centre/Lawson Health Research Institute.

    Dr. Robert Wolfert

    Industry Executive

    Dr. Wolfert is an accomplished R&D and management executive with over 25 years of experience. His background includes extensive ground-level startup and early-stage company management experience in the in vitro diagnostics industry. Dr. Wolfert has designed and managed R&D programs through all stage of phase-gated Design Controls processes, designed and directed clinical trials to support PMA and 510(k) submissions to the FDA, and established and maintained a CLIA/CAP certified testing laboratory. In addition to his broad knowledge of the IVD industry, much of his work focused on prostate cancer specifically. Dr. Wolfert has recently served as a VP for both Mesoscale Diagnostics and Metabolon Inc and the Executive VP and Chief Scientific Officer of diaDexus. He completed his BA at Cornell University, his PhD at Tufts University, and a Postdoctoral Fellowship at the Scripps Clinic and Research Foundation.

    Dr. Michael Feloney

    Uro Oncologist- Creighton University School of Medicine

    Dr. Feloney is the Chairman of the Department of Urology at Creighton University School of Medicine in Omaha, Nebraska and is the co-founder and president of F&S Medical Solutions. He is a surgeon double boarded in Urology and Female Pelvic Medicine and Reconstructive Surgery. Dr. Feloney has matriculated through three Jesuit Universities. He received his BS degree from Santa Clara University, his MD degree from Saint Louis University, and has an MBA from Creighton University. Dr. Feloney’s internship in general surgery and residency in urologic surgery was completed at the University of Oklahoma in Oklahoma City. His fellowship in female pelvic medicine and reconstructive surgery was completed at University of Medicine and Dentistry of New Jersey in Camden, New Jersey and at Drexel University College of Medicine in Philadelphia, Pennsylvania.

  • Investors

    Thankful to have investors involved in Gregor beyond just a check!

All Posts